Back to Search
Start Over
NOVEL IRON BIOMARKERS IN CHRONIC KIDNEY DISEASE.
- Source :
-
Wiadomosci lekarskie (Warsaw, Poland : 1960) [Wiad Lek] 2021; Vol. 74 (12), pp. 3230-3233. - Publication Year :
- 2021
-
Abstract
- CKD is one of the fastest growing causes of death in the world and in 2040, it is estimated that it will be in the top five causes of death. In order to slow down this process, it is necessary to improve prevention, inhibit development and treat complications including anemia. Anemia is one of the common complication of chronic kidney disease (CKD), which is a significant clinical problem. It is most often the result of decreased renal production of erythropoietin and / or iron deficiency. Iron deficiency anemia is one of the most common problems in CKD that increases mortality. In order to successfully treat anemia in CKD with erythropoiesis-stimulating agentsand (ESA) and iron substitution, it is necessary to determine iron iron level. The diagnosis of iron deficiency anemia in patients with CKD is complicated due to the relatively low predictive ability of routine serum iron markers (e.g., ferritin and transferrin saturation) and more invasive measurements such as bone marrow iron stores. In the review novel biomarkers of iron metabolism are discussed such as hypoxia-inducible factor, erythroferon, growth differentiation factor 15 etc. with their possible clinical relevance.
Details
- Language :
- English
- ISSN :
- 0043-5147
- Volume :
- 74
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Wiadomosci lekarskie (Warsaw, Poland : 1960)
- Publication Type :
- Academic Journal
- Accession number :
- 35058395